Medicure (MCUJF) Stock Price, News & Analysis

Company Overview

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Key Stats

• Today's Range: $0.77 to $0.77
• 50-Day Range: $0.77 to $0.94
• 52-Week Range: $0.44 to $0.94
• Volume: 1,000 shs
• Average Volume: 107 shs
• Market Capitalization: $8.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Medicure Stock Analysis - MarketRank™

Medicure scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Medicure.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Medicure is -7.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Medicure is -7.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Medicure has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the outstanding shares of Medicure have been sold short.

Short Interest Ratio / Days to Cover

Medicure has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Medicure has recently decreased by 71.43%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Medicure does not currently pay a dividend.

Dividend Growth

Medicure does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the outstanding shares of Medicure have been sold short.

Short Interest Ratio / Days to Cover

Medicure has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Medicure has recently decreased by 71.43%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.9 / 5
• News Sentiment: N/A

News Sentiment

Medicure has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Medicure this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Medicure insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.90% of the stock of Medicure is held by insiders. A high percentage of insider ownership can be a sign of company health.

MCUJF Stock Analysis - Frequently Asked Questions

How have MCUJF shares performed this year?

Medicure's stock was trading at $0.62 at the start of the year. Since then, MCUJF shares have increased by 24.2% and is now trading at $0.77.

How were Medicure's earnings last quarter?

Medicure Inc. (OTCMKTS:MCUJF) announced its quarterly earnings results on Wednesday, August, 20th. The company reported ($0.06) earnings per share (EPS) for the quarter. The company earned $4.82 million during the quarter. Medicure had a negative trailing twelve-month return on equity of 6.65% and a negative net margin of 5.70%.

How do I buy shares of Medicure?

Shares of MCUJF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/20/2025
• Today: 8/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MCUJF
• CIK: 1133519
• Web: www.medicure.com
• Phone: (204) 487-7412
• Fax: 204-488-9823
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$760 thousand
• Net Margins: -5.70%
• Pretax Margin: -4.85%
• Return on Equity: -6.65%
• Return on Assets: -4.52%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 1.48
• Quick Ratio: 1.06

Sales & Book Value

• Annual Sales: $15.99 million
• Price / Sales: 0.50
• Cash Flow: $0.09 per share
• Price / Cash Flow: 8.63
• Book Value: $1.45 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 10,440,000
• Free Float: 9,090,000
• Market Cap: $8.04 million
• Optionable: Not Optionable
• Beta: 1.07